secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001558370-24-000019
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios Therapeutics: FDA alignment on Phase 3 fibromyalgia and Phase 2 Long-COVID endpoint clarity
--------------------------------------------------------------------------------

- FDA agreed on Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia treatment.
- FDA accepted fatigue as primary endpoint and orthostatic intolerance as key secondary for IMC-2 Long-COVID Phase 2 study.
- Company provided unrestricted grant to Bateman Horne Center for placebo-controlled study of up to 60 LC patients on IMC-2.
- New international patent application filed for IMC-2 as treatment for Long-COVID and fatigue conditions.
- Company has capital to support operations into Q4 2024; exploring M&A opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024000019/0001558370-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024000019/tmb-20240103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer